See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Supplementary Medicine, New Products & Services
First Painless Laser Treatment for Acne Introduced
Aesthera's Isolaz (Deep Pore Lazr Therapy) with Photopneumatic technology
offers novel pore purification to clear widest range of acne types
PLEASANTON, Calif., May 22 /PRNewswire/ -- Aesthera Corporation, the
pioneer of technologically advanced PhotopneumaticTM (PPx(TM)) aesthetic
systems, announced today the arrival of its newest painless laser therapy -
Isolaz(TM) (Deep Pore Lazr Therapy) - into the consumer marketplace.
Powered by Photopneumatic Technology, the Isolaz helps destroy acne causing
bacteria with a combination of pneumatic energy (vacuum) and laser light
for a dramatic pore purifying therapy that helps clears acne fast.
Aesthera's Isolaz(TM) (Deep Pore Lazr Therapy) offers the broadest
indications of any laser or light-based system available on the market
today and is the only system FDA cleared to treat comedonal and pustular
acne. In addition, the Isolaz(TM) therapy is cleared to treat mild to
moderate, inflammatory acne and acne vulgaris.
In addition to acne reduction, a recent clinical study showed that 64
percent of acne patients who had not responded to oral medications,
topicals and traditional lasers in the past had shown greater than a 75
percent clearance of acne lesions after treatment with the Isolaz(TM)
system (i). After four treatments, an 88 percent reduction in papular,
pustular, comedonal and nodular acne was observed(ii).
"The Isolaz(TM) treatment is the new gold-standard that physicians and
consumers should look to when treating acne, as it is the only technology
that literally cleans the pores from the inside out," states Alon Maor,
Co-Founder, President & CEO of Aesthera Corporation. "In contrast to
traditional therapies, because the Isolaz system deep purifies the pores,
many patients experience immediate gratification with noticeably clearer
skin tone and texture as well as reduced pore size after the first
treatment."
Patients that undergo Isolaz(TM) (Deep Pore Lazr Therapy) do not
experience side effects commonly associated with lasers and acne
treatments, such as redness, peeling or sun sensitivity. Additionally,
immediate improvements are generally seen within the 24-48 hours of the
first Isolaz(TM) treatment including a drying and flattening of the lesion.
Finally, Isolaz treatments are fast and can be performed in around 10
minutes so you can have them done during lunch. Isolaz(TM) treatments also
do not require pre- treatment and/or topical anesthetics.
Along with being cleared for acne, the Isolaz(TM) is also FDA cleared
for the treatment of vascular and pigmented lesions as well as permanent
hair reduction.
Isolaz(TM) acne therapy is offered on all of Aesthera's Isolaz(TM) and
PPx(TM) systems. Currently there are over 1000 systems available worldwide.
To learn were you can receive an Isolaz(TM) treatment or if you would like
to receive more information on the Isolaz(TM) System please call
877.275.4779, email WeListen@AESTHERA.com or visit www.ISOLAZ.com.
About Aesthera Corporation
Aesthera (www.AESTHERA.com) develops, manufactures and markets
light-based aesthetic treatment systems based on proprietary
Photopneumatic(TM) (PPx(TM)) technology. Clinically proven to be pain-free
and up to seven times faster than currently available light-based aesthetic
systems, Aesthera's revolutionary systems combine the proven properties of
therapeutic light with gentle pneumatic energy to more effectively work on
dermal and epidermal skin targets. Aesthera allows physicians to provide
powerfully painless aesthetic treatments in a system with very low
cost-to-own and near-immediate profitability -- giving them the opportunity
to provide best-in-class service.
i. Photopneumatic (PPx) Pore-Cleansing Acne Treatment: A breakthrough
treatment option for Non-Responders to Acne Therapies, Ava T. Shamban, MD,
Laser Institute for Dermatology and European Skin Care, Santa Monica, CA,
October 2006.
ii. Multi-Center Data submitted to FDA, Aesthera Corporation, July
2006.
SOURCE Aesthera Corporation
Back to top
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".
